Cabozantinib Plus Atezolizumab Delays Progression in mCRPC

Combination improved PFS versus more hormonal therapy, but control arm questioned

Related Keywords

Massachusetts ,United States ,United Kingdom ,Vancouver ,British Columbia ,Canada ,Salt Lake City ,Utah ,University Of Utah ,British ,Mike Bassett ,Neeraj Agarwal ,Kimn Chi ,British Columbia Cancer Agency ,Huntsman Cancer Institute ,Genitourinary Cancers ,